BBS Faculty Member - Myles Brown

Myles Brown

Department of Medicine, DFCI and HMS
Director, Center for Functional Cancer Epigenetics, DFCI

Dana-Farber Cancer Institute
Dana Building, Room D730
450 Brookline Ave.
Boston, MA 02115
Tel: 617-632-3948
Fax: 617-582-8501
Visit my lab page here.

The primarily focus of the work in my laboratory is the molecular understanding of the action of steroid hormone receptors and their role in human cancer. We were the first to identify the p160 class of steroid receptor coactivators and to show that coregulators play an important role in the tissue and promoter selective action of steroid hormone receptors and their ligands. My lab was the first to define steroid receptor binding sites on a genome-wide scale. This led to the concept of the cistrome, the set of cis-acting targets of a trans-acting factor across the genome. Most recently we have used ChIP-seq to define the epigenomic and cistromic changes that underlie the development of hormone independent cancer. Together with Shirley Liu I direct the Center for Functional Cancer Epigenetics at the Dana-Farber. The experimental platforms and computational expertise of the center is available to support the work of the trainees in my lab.

Last Update: 8/22/2013


Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff, PW, Liu XS, Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009 Jul 23;138(2):245-56.

Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M. Growth factor stimulation induces a distinct ER
cistrome underlying breast cancer endocrine resistance. Genes Dev. 2010 Oct 1;24(19):2219-27.

Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011 Jul 12;20(1):119-31.

Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M. EZH2 oncogenic activity in castration resistant prostate cancer cells is polycomb-independent. Science 2012 (in press).

© 2016 President and Fellows
of Harvard College